Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS

Area of Science:

• Neuroscience
• Metabolomics
• Biochemistry

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with a poor prognosis.
• Current diagnostic and prognostic tools for ALS are limited.
• Biomarkers and metabolic signatures are needed for effective ALS management.

Purpose of the Study:

• To investigate the cerebrospinal fluid (CSF) lipidomic signature in ALS patients.
• To evaluate the diagnostic and predictive value of CSF lipid profiles in ALS.
• To identify specific lipids associated with ALS and its clinical progression.

Main Methods:

• Cerebrospinal fluid (CSF) samples from ALS patients (n=40) and controls (n=45) were analyzed using mass spectrometry.
• Lipidomic profiles were compared between groups to identify discriminant molecules.
• Targeted lipid analysis was performed in the brain cortex of ALS model mice.
• Machine learning models were used to predict ALSFRS-r score variations from baseline lipidome.

Main Results:

• ALS patients exhibited a distinct CSF lipidomic signature compared to controls.
• Phosphatidylcholine PC(36:4) was the most significant discriminant molecule, elevated in ALS patients (p=0.0003).
• Ceramides, glucosylceramides, sphingomyelins, and triglycerides were also identified as relevant lipids.
• Models predicted ALSFRS-r score variations with 71% accuracy in an independent patient set.
• Clinical evolution predictions correlated with specific sphingomyelins and triglycerides.

Conclusions:

• The study reveals extensive lipid remodeling in the CSF of ALS patients.
• A novel metabolic signature for ALS and its clinical evolution has been identified.
• The identified lipid signature demonstrates good diagnostic and predictive performance for ALS.